Cupid Ltd - Q3FY24 Results Release - Reports Robust Earnings for Q3FY24, PAT Grows 73% QoQ
Cupid Ltd. Reports Robust Earnings for Q3FY24, PAT Grows 73% QoQ
Revenue from Operations reported at Rs. 40.05 Cr in Q3FY24
EBITDA came in at Rs. 12.15 Cr in Q3FY24
PAT stood at Rs. 8.86 Cr in Q3FY24
Board Approves Stock Split, Bonus Issue and Preferential Issue to FIIs
of Convertible warrants on Preferential basis to FIIs for Rs. 385 crores.
Standalone Financial Statement Highlights for Q3FY24 vs Q2FY24 vs Q3FY23
Standalone Financial Performance Comparison – Q2FY24 v/s Q3FY24
Revenue from Operations grew by 16% from Rs. 34.46 Cr in Q2FY24 to Rs. 40.05 Cr in Q3FY24.
EBITDA increased by 132% from Rs. 5.22 Cr in Q2FY24 to Rs. 12.15 Cr in Q3FY24
PAT increased by 73% from Rs. 5.11 Cr in Q2FY24 to Rs. 8.86 Cr in Q3FY24.
Management Comments
“We are pleased to announce the financial results for the third quarter of the fiscal year 2023-24, reflecting a robust
performance across key financial indicators. Our Revenue from Operations witnessed a commendable growth of 16%,
reaching Rs. 40.05 Cr in Q3FY24, compared to Rs. 34.46 Cr in the preceding quarter. This growth underscores our
resilient business model and effective execution of our strategic initiatives.
A significant improvement was evident in our EBITDA, which surged from Rs. 5.22 Cr in Q2FY24 to Rs. 12.15 Cr in
Q3FY24 by 132%..
Furthermore, the Profit After Tax (PAT) registered a noteworthy increase of 73%, climbing from Rs. 5.11 Cr in Q2FY24
to Rs. 8.86 Cr in Q3FY24.
Additionally, we are delighted to share the exciting news of our recent acquisition of a new land parcel in the MIDC
Area, first announced in December 2023. This strategic move is poised to significantly enhance our production
capabilities, solidifying our position in the global market. The acquisition will augment our production capacity by 1.5
times the existing output, enabling us to produce approximately 770 million male condoms and 75 million female
condoms annually, in addition to our current capacity of 480 million male condoms and 50 million female condoms.
Board of Directors approved a stock split of 10:1 and a bonus share issue of 1:1 in order to enhance shareholder value
further. With this decision, we are ensuring that our shareholders' interests are aligned with ours.
Finally the Board has approved the preferential issue of 22,00,000 convertible warrants totaling Rs. 385 crores. These
warrants are proposed to be allocated to reputed entities such as Forbes EMF, Elara India Opportunities Fund Limited,
Aries Opportunities Fund Limited, Arrow Emerging Opportunities Fund Limited, Zeal Global Opportunities Fund, Nova
Global Opportunities Fund PCC Touchstone. The preferential issue is priced at Rs. 1750 per warrant. The capital infusion
will help us strengthen our financial position and support our ambitious growth plans. The collaboration with these
esteemed investors underscores their confidence in our business and future prospects.
We remain optimistic about the future and are confident that these strategic initiatives will contribute to sustained
growth, solidifying our position. We appreciate the continued support of our shareholders, customers, and stakeholders
as we pursue our commitment to excellence and value creation.”
Comments
Post a Comment